Published on 29/11/2025

Governance for ATMP Validation across Sites

Introduction to Advanced Therapy Medicinal Products (ATMP)

Advanced Therapy Medicinal Products (ATMPs) represent a transformative class of therapies that include gene therapy, somatic cell therapy, and tissue-engineered products. With their complex nature, the validation processes for ATMPs are critical to ensure safety, efficacy, and compliance with regulatory expectations laid out by authorities like the FDA, EMA, and MHRA. The governance of validation across multiple sites is particularly important given the intricate variables that can influence product quality and patient safety.

As ATMP products often involve biological materials, ensuring adherence to good manufacturing practices (GMP) is paramount. This article provides a comprehensive step-by-step tutorial on governance for ATMP validation, focusing on aspects such as viral clearance validation, process performance qualification (PPQ), and critical quality attributes (CQAs).

Step 1: Understanding Regulatory Framework for ATMP Validation

To effectively govern ATMP validation, one must have a thorough understanding of the regulatory requirements applicable in different regions such as the US, UK, and EU. The FDA outlines its expectations in various documents, including Guidance for Industry: Gene Therapy for Rare Diseases, while the EMA provides the Guideline on Human Gene Therapy Medicinal Products. These resources articulate key considerations for safety, quality, and efficacy testing.

The MHRA and PIC/S also offer guidance aligned with ICH Q5A(R2), which addresses the viral safety of biotechnology products derived from cell lines of human or animal origin. Understanding this regulatory landscape is vital for establishing a robust governance framework.

Step 2: Tailoring Process Performance Qualification (PPQ) for ATMP

The tailoring of PPQ for ATMP requires careful consideration of the unique characteristics of biological products. Unlike traditional small molecules, ATMPs are susceptible to variations in the manufacturing process, necessitating a strategic approach to qualification. The integration of potency identity CQAs into the PPQ is crucial. This includes parameters such as product concentration, specific activity, and identity verification.

Effective PPQ should encompass the following key elements:

• Definition of Test Conditions: Establish specific parameters for testing, considering the unique conditions of each site where ATMP is produced.
• Spiking Studies: Implement studies using viral or other relevant contaminants to evaluate the robustness of the process and ensure that critical control steps are effective.
• Longitudinal Studies: Collect ongoing data from multiple production lots to analyze variability and maintain consistency across production sites.

Specific methodologies such as closed systems and single-use systems can also help mitigate contamination risks during processing. These systems promote aseptic processing by reducing human intervention and environmental exposure.

Step 3: Conducting Viral Clearance Validation

Viral clearance validation is a crucial aspect of the ATMP development process. This validation serves to demonstrate that the manufacturing process effectively removes or inactivates potential viral contaminants. Following the guidelines outlined in the ICH Q5A(R2), validation should be conducted in multiple stages, including:

• Risk Assessment: Identify potential viral contaminants based on source materials and the manufacturing process.
• Process Evaluation: Assess existing purification steps for their capacity to remove or inactivate viruses.
• Spiking Studies: These studies should analyze specific viral strains to validate the effectiveness of the clearance mechanisms, assessing their performance over a range of conditions.
• Documentation and Reporting: Maintain detailed records of findings from viral clearance studies, ensuring compliance with regulatory requirements.

Step 4: Implementing Aseptic Controls in Accordance with Annex 1 Guidelines

Aseptic processing controls are fundamental for ATMPs, particularly when accounting for Annex 1 of the EU GMP guidelines, which provides specific directives for aseptic manufacturing. Key principles include:

• Environmental Monitoring: Regular monitoring of the clean room environment to detect any microbial contamination is essential.
• Personnel Training: Ensure all personnel are trained in aseptic techniques and understand the critical control points within the manufacturing process.
• Equipment Qualification: Validate all equipment used in the manufacturing process, ensuring it meets stringent GMP requirements. This includes evaluating closed and single-use systems, which can further reduce contamination risks.

Applying a risk-based approach to aseptic processing will enhance product safety and compliance with established benchmarks.

Step 5: Establishing Chain of Identity (COI) and Chain of Custody (COC)

The management of Chain of Identity (COI) and Chain of Custody (COC) is critical in validating ATMPs, particularly due to the biological nature of the product. Ensuring that the patient-specific cells or materials remain linked to their intended application is a regulatory requirement. To effectively manage COI and COC, organizations should:

• Implement Robust Tracking Systems: Employ electronic tracking systems that document every transition of materials from collection to administration.
• Conduct Periodic Audits: Regularly review the COI and COC processes to identify and rectify potential discrepancies.
• Cross-functional Collaboration: Foster collaboration between clinical operations, production, and regulatory affairs teams to maintain stringent oversight and compliance.

Step 6: Continuous Monitoring and Quality Assurance (QA) Integration

Once the governance framework is established, continuous monitoring must be executed as part of the Quality Assurance (QA) program. This integrates various QA methodologies into the ATMP production lifecycle, ensuring constant adherence to regulatory requirements.

Key components of QA monitoring include:

• Batch Record Reviews: Continually review and assess batch records for compliance with established procedures and regulations.
• Deviation Management: Establish processes for identifying, documenting, and investigating deviations from pre-defined processes.
• Regulatory Compliance Audits: Regularly conduct internal audits to ensure adherence to FDA, EMA, and other relevant regulations.

Step 7: Final Review and Approval Processes

Before ATMP products are released for clinical use, a final review and approval process must be in place. This process helps assert that all necessary documentation, confirmations, and regulatory compliances have been met.

Essential steps include:

• Compilation of Validation Reports: Assemble complete validation reports summarizing findings and evidence from all validation steps.
• Regulatory Submissions: Prepare and submit necessary documentation to regulatory agencies for review and approval.
• Stakeholder Communication: Keep all stakeholders informed on the final product status, including any potential concerns that might have arisen during the validation process.

Conclusion

The governance of ATMP validation across different sites is a complex but essential endeavor that necessitates a multi-faceted approach, adhering to both regulatory and operational standards. From understanding the regulatory landscape to implementing tailored PPQ strategies, conducting thorough viral clearance validations, and ensuring stringent aseptic controls, every step is integral to assuring the final product’s safety and efficacy.

As this field evolves, it is imperative for pharmaceutical professionals to remain informed and engaged, leveraging both best practices and regulatory guidance to pave the way for successful ATMP developments. By advocating for rigorous validation practices, companies not only comply with current standards but also contribute to advancing therapeutic options grounded in safety and efficacy.